Clinical Trial Update: Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

This document describes the completion and results posting of a Phase 3 pediatric trial evaluating long-term safety, tolerability, and efficacy of secukinumab i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Plaque-type

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Moderate to Severe Chronic Plaque-type Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2021-07-23